An Extension Study to CIGE025B1301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children (6 - 15 Years) With Inadequately Controlled Allergic Asthma Despite Current Recommended Treatment

Trial Profile

An Extension Study to CIGE025B1301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children (6 - 15 Years) With Inadequately Controlled Allergic Asthma Despite Current Recommended Treatment

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Nov 2016

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Allergic asthma
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 29 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 26 Feb 2013 New trial record
    • 11 Feb 2013 Planned end date changed from February 2014 to May 2014, according to the ClinicalTrials.gov record..
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top